Histone Deacetylase Inhibitors as Anticancer Drugs
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy. HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDAC inhibitors are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed. Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance. Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclinical and clinical studies, including the combination with other therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [164]
In the citing paper
“HDAC inhibitors act as antitumoral agents by antagonizing the pro-transcriptional effects of histone deacetylation and silencing the expression of oncogenic factors through chromatin remodeling43.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 105 · cited 2×
“SAHA carfilzomib in vitro and nude mice xenografts, lymphoma cell SUDHL16, SUDHL4 , SUDHL6, OCI-LY10, OCI-LY3 bortezomib-resistant SUDHL16-10BR, OCI-LY10-40BR and lymphoma cells frompatients Potentiation [152]”
BackgroundRetractedDasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 57 · cited 2×
“SNDX-275, SAHA carfilzomib, bortezomib in vitro and nude mice xenografts, lymphoma cell Granta 519, Rec-1, HF-4B, JVM-2, MINO, JVM-13 Potentiation [153]”
BackgroundRetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31 · cited 3×
“Moreover, inhibition of HDAC6 activates naïve T cells [119,120].”
BackgroundRetractedThe Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325 · cited 1×
“The Wnt signaling pathway plays an important role in various cancers such as colon, breast, ovarian, prostate and endometrial cancers as well as medulloblastoma and melanoma [103].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Several tumor associated antigens have been shown to be epigenetically silenced in malignancies impede immune recognition by cytotoxic T cells and contributing to worse prognosis [124,125].”
BackgroundActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · cited 2×
“Therefore, HDACs may be essential for the maintenance of a set of key genes required for survival and growth of cancer cells but not of normal ones [38].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HATs catalyze the transfer of an acetyl group from acetyl-CoA to the ε-NH2 group of lysine residues in proteins, while HDACs remove it [12].”
BackgroundRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608 · cited 1×
“eNOS, Akt in vitro endothelial cells, Akt transfected, mutatnteNOS / [110]”
Background
Cited by
Items 501–600 of 1,000
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
Oltra, S. S., Cejalvo, J. M., Tormo, E., Albanell‐Fernández, M., Ferrer, A., Nacher, M., Bermejo, B., Hernándo, C., Chirivella, I., Alonso, E., et al. (2020) · Cancers · doi:10.3390/cancers12020412 · Cited by 20
“Carcinogenesis can be explained by genetic alterations, but epigenetic processes such as DNA methylation, histone modifications, and non‐coding RNA deregulation are also involved [8].”
BackgroundYang, M., Mao, S., Duan, J., & Xiao, P. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.124723 · Cited by 19
Deciphering novel chemotherapy and its impact on dentistry
King, R., Zebic, L., & Patel, V. (2020) · BDJ · doi:10.1038/s41415-020-1365-5 · Cited by 19
Romeo, M. A., Montani, M. S. G., Benedetti, R., Arena, A., D’Orazi, G., & Cirone, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042268 · Cited by 20
“The targeting of HDACs has been demonstrated to be an effective anticancer approach as single agents, against pancreatic [18,27] as well as other solid [13] or hematologic cancer types [11,28].”
BackgroundAbbas, E. M. H., Farghaly, T. A., Sabour, R., Shaaban, M. R., & Abdallah, Z. A. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200076 · Cited by 18
Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells
Tsai, F.-L., Huang, H.-L., Lai, M.-J., Liou, J., Pan, S., & Yang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612588 · Cited by 19
“Histone deacetylase inhibitors were extensively studied, showing profound cytotoxic effects by inducing cell cycle arrest and apoptosis [37].”
BackgroundDysregulation of histone deacetylases in ocular diseases
Jun, J. H., Kim, J.-S., Palomera, L. F., & Jo, D. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01482-x · Cited by 19
Effect of valproic acid on histone deacetylase expression in oral cancer (Review)
Al-Khafaji, A. S., Wang, L. M., Alabedi, H. H. O., & Liloglou, T. (2024) · Oncology Letters · doi:10.3892/ol.2024.14330 · Cited by 19
“Among these are pan‑HDACis, which inhibit all HDAC classes, while others exert specificity against certain HDAC classes (29).”
InfluentialBiological Profile of Synthetic and Natural Indole Derivatives: Paving New Paths in Cancer Treatment
Janeiro, A. M., & Marques, C. S. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3030029 · Cited by 18
Delta-like 3 is silenced by HBx via histone acetylation in HBV-associated HCCs
Hamamoto, H., Maemura, K., Matsuo, K., Taniguchi, K., Tanaka, Y., Futaki, S., Takeshita, A., Asai, A., Hayashi, M., Hirose, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23318-1 · Cited by 19
Ishola, A. A., & Adewole, K. E. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04689-8 · Cited by 18
Al-Amily, D. H., & Mohammed, M. H. (2019) · Scientia Pharmaceutica · doi:10.3390/scipharm87040028 · Cited by 18
Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses
Ciechomska, I. A., Jayaprakash, C., Maleszewska, M., & Kaminska, B. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-30651-9_13 · Cited by 19
Beyond regulations at DNA levels: A review of epigenetic therapeutics targeting cancer stem cells
Zhang, S., Gong, Y., Li, C., Yang, W., & Li, L. (2020) · Cell Proliferation · doi:10.1111/cpr.12963 · Cited by 19
Wang, C.-A., Li, C., Huang, R.-C., Li, Y.-H., Liou, J., & Tsai, S. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0963 · Cited by 18
Bai, M., Cui, M., Li, M., Yao, X., Wu, Y., Zheng, L., Sun, L., Song, Q., Wang, S., Liu, L., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.62339 · Cited by 18
“Histone deacetylases (HDACs) and histone acetyltransferases (HATs) [1] regulate gene expression via chromatin modification [2].”
BackgroundHistone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
Psilopatis, I., Pergaris, A., Giaginis, C., & Theocharis, S. E. (2021) · Disease Markers · doi:10.1155/2021/7850688 · Cited by 23
“Few HDACIs have already received FDA approval for T-cell lymphoma or multiple myeloma, yet there is a great number of current clinical trials investigating the role of HDACIs (alone or in combination with other anticancer drugs) in the treatment of numerous solid cancer entities [22, 23].”
BackgroundEvaluation of the antioxidative and genotoxic effects of sodium butyrate on breast cancer cells
Yüksel, B., Özkan, A. D., Aydın, D., & Betts, Z. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.12.061 · Cited by 20
Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas
Lanzi, C., & Cassinelli, G. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114944 · Cited by 19
Whitmore, M. A., Li, H., Lyu, W., Khanam, S., & Zhang, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.874706 · Cited by 18
“org 9 It is noted that butyrate, vorinostat (also known as suberoylanilide hydroxamic acid or SAHA), and mocetinostat are all pan-HDACi capable of inhibiting multiple classes of HDAC (45).”
BackgroundA review on Hydroxamic Acids: Widespectrum Chemotherapeutic Agents
(2020) · International Journal of Biology and Biomedical Engineering · doi:10.46300/91011.2020.14.12 · Cited by 18
Histone deacetylase inhibitors as antidiabetic agents: Advances and opportunities
Sonthalia, M., Roy, B. S., Chandrawanshi, D., Ganesh, G. V., Jayasuriya, R., Mohandas, S., Rajagopal, S., & Ramkumar, K. M. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175328 · Cited by 18
Mizuno, Y., Maemura, K., Tanaka, Y., Hirata, A., Futaki, S., Hamamoto, H., Taniguchi, K., Hayashi, M., Uchiyama, K., Shibata, M., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6293 · Cited by 18
Lin, C.-W., Septyaningtrias, D. E., Chao, H., Konda, M., Atarashi, K., Takeshita, K., Tamada, K., Nomura, J., Sasagawa, Y., Tanaka, K. Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01566-y · Cited by 17
“VPA is also short-chain fatty acid and potent Class I/IIa HDAC inhibitor, which is registered as the therapy for epilepsy and has been used in clinical trials of hematologic malignancies [46].”
BackgroundMethodKawamura, Y., Hua, L., Gurtner, A., Wong, E., Kiyokawa, J., Shah, N., Gorham, J., Wakimoto, H., Rabkin, S. D., Martuza, R. L., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113843 · Cited by 19
“We selected Pano for in vivo studies with MM xenografts, since Pano was approved for the treatment of multiple myeloma, while TSA is a preclinical agent [27].”
Nazri, J. M., Οικονομοπούλου, Κ., de Araujo, E. D., Kraskouskaya, D., Gunning, P. T., & Chandran, V. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2177251 · Cited by 17
“Although the role of HDAC inhibitors in promoting autophagy upon cancer cell death remains controversial, several signaling pathways and acetylation of many autophagy-related proteins have been identified [141].”
BackgroundUba, A. İ., & Zengin, G. (2023) · Amino Acids · doi:10.1007/s00726-023-03297-y · Cited by 17
“According to their chemical structures, HDAC inhibitors are categorized into four types: hydroxamic acids, benzamides, cyclic peptides or depsipeptides, and aliphatic carboxylic acids (Eckschlager et al. 2017).”
Epigenetic hallmarks in pulmonary fibrosis: New advances and perspectives
Zhang, Y.-S., Tu, B., Song, K., Lin, L.-C., Liu, Z., Lu, D., Chen, Q., & Tao, H. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110842 · Cited by 18
Zichittella, C., Loria, M., Celesia, A., Liberto, D. D., Corrado, C., Alessandro, R., Emanuele, S., & Conigliaro, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1275833 · Cited by 17
“Numerous studies propose the therapeutic use of histone deacetylase inhibitors (HDACis) for the treatment of several diseases, including metabolic, inflammatory, autoimmune, and neurodegenerative diseases, and not least for the treatment of cancer (Eckschlager et al., 2017; Vagapova et al., 2021; Squarzoni et al., 202…”
BackgroundRaouf, Y. S., Sedighi, A., Geletu, M., Frere, G. A., Allan, R. G., Nawar, N., de Araujo, E. D., & Gunning, P. T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01236 · Cited by 17
Maeshima, K. (2025) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.101.020 · Cited by 22
“106) – 109)”
Chromatin as a Platform for Modulating the Replication Stress Response
Fournier, L.-A., Kumar, A., & Stirling, P. C. (2018) · Genes · doi:10.3390/genes9120622 · Cited by 20
Sun, J., Qian, X., Zhang, F., Tang, X., Ju, C., Liu, R., Zhou, R., Zhang, Z., Lv, X., Zhang, C., et al. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.10.30 · Cited by 17
“Thus, HDAC inhibitors have become a new treatment strategy for cancer (28,29).”
BackgroundValproic acid-induced changes of 4D nuclear morphology in astrocyte cells
Kalinin, A. A., Hou, X., Ade, A. S., Fon, G.-V., Meixner, W., Higgins, G. A., Sexton, J. Z., Wan, X., Dinov, I. D., O’Meara, M. J., et al. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-08-0502 · Cited by 20
Wang, J., Zhang, Q., Li, Q., Mu, Y., Jing, J., Li, W., Li, W., Wang, J., Yu, G., Wang, X., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00823-4 · Cited by 18
“Histone deacetylases (HDACs), which remove the acetyl groups from lysines that have been N-acetylated by histone acetylases, target epigenetic changes in tumors and alter gene regulation; they have recently become important targets for anti-tumor drug design [12].”
BackgroundLamoine, S., Cuménal, M., Barrière, D. A., Pereira, V., Fereyrolles, M., Prival, L., Barbier, J., Boudieu, L., Brasset, É., Bertin, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010098 · Cited by 20
“The well-tolerated epigenetic drug MS-275 was tested in phase III clinical trials for the treatment of various tumor entities [70].”
MethodMarek, M., Ramos‐Morales, E., Picchi, G. F. A., Bayer, T., Norström, C., Herp, D., Sales-Junior, P. A., Guerra-Slompo, E. P., Hausmann, K., Chakrabarti, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110129 · Cited by 18
Xu, L., Wang, J., Liu, B., Fu, J., Zhao, Y., Yu, S., Shen, L., Yan, X., & Su, J. (2022) · Biomedicines · doi:10.3390/biomedicines10020374 · Cited by 21
“HDAC inhibitors seem to be promising anticancer drugs, especially in combination with other anticancer drugs and/or radiotherapy [39,40].”
BackgroundOmidkhah, N., Hadizadeh, F., Zarghi, A., & Ghodsi, R. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03018-w · Cited by 20
Schnekenburger, M., Mathieu, V., Lefranc, F., Jang, J. Y., Masi, M., Kijjoa, A., Evidente, A., Kim, H., Robert Kiss, A., Dicato, M. A., et al. (2018) · Molecules · doi:10.3390/molecules23020333 · Cited by 17
“HDAC inhibitors (HDACi) of class I, II, and IV are the most widely used for basic research as well as in the clinic [12,13]; however, sirtuin inhibitors (SIRTi) represent a novel, attractive approach for anti-cancer drug development [6,7].”
BackgroundEnzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer
Carafa, V., Poziello, A., Torre, L. D., Giovannelli, P., Donato, M. D., Safadeh, E., Yu, Z., Baldi, A., Castoria, G., Tomaselli, D., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225654 · Cited by 17
Ghanghas, P., Sharma, M., Desai, D. H., Raza, K., Bhalla, A., Kumar, P., Narula, D., Amin, S., Sanyal, S. N., & Kaushal, N. (2021) · Biological Trace Element Research · doi:10.1007/s12011-021-02659-5 · Cited by 17
Wei, Y., Guo, Y., & Lv, S. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115521 · Cited by 17
Wang, P., Zhao, C., Zhou, H., Huang, X., Ying, H., Zhang, S., Pan, Y., & Zhu, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511899 · Cited by 20
“HDAC1-null mice will die prenatally with a severe proliferation defect and general growth retardation [21].”
BackgroundA review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
Selim, O. A., Song, C. H., Kumar, A. E., Phelan, R., Singh, A. S., & Federman, N. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1244035 · Cited by 16
“At present, the FDA has approved four HDACi for cutaneous/peripheral T-cell lymphoma (9, 10).”
BackgroundThe Roles of Histone Deacetylases in the Regulation of Ovarian Cancer Metastasis
Xu, L., Yan, X., Wang, J., Zhao, Y., Liu, Q., Fu, J., Shi, X., & Su, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015066 · Cited by 17
“Additionally, a variety of HDACIs have been investigated in clinical trials, including CS055, quisinostat, MS-275 and 4SC202 [16].”
BackgroundFerrario, N., Marras, E., Vivona, V., Randisi, F., Fallica, A. N., Marrazzo, A., Perletti, G., & Gariboldi, M. B. (2024) · Cancers · doi:10.3390/cancers16122227 · Cited by 18
“HDAC) inhibitors, thus exerting their effect by influencing epigenetic and non-epigenetic pathways inducing cell death and cell cycle arrest in cancer cells [45].”
BackgroundPerez, J. E. T., Zhang, S., Hodgeman, W., Kapoor, S., Rajendran, P., Kobayashi, K. S., & Dashwood, R. H. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01698-8 · Cited by 20
“Another approach might be to combine HDAC inhibition with standard of care chemotherapy [77].”
BackgroundJia, X., Zheng, Y.-S., Guo, Y., & Chen, K. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.613 · Cited by 16
“HDACIs have been classified into five main classes according to their specificity for HDAC subtypes: (1) Hydroxamic acids; (2) Short–chain fatty acids; (3) Benzamides; (4) Cyclic tetrapeptides; (5) Sirtuin inhibitors, including the pan‐inhibitor nicotinamide (Eckschlager et al., 2017).”
BackgroundHa, Y. N., Song, S., Orlikova-Boyer, B., Cerella, C., Christov, C., Kijjoa, A., & Diederich, M. F. (2020) · Marine Drugs · doi:10.3390/md18010057 · Cited by 16
“SAHA: Suberoylanilide hydroxamic acid.”
BackgroundMetruccio, F., Palazzolo, L., Renzo, F. D., Battistoni, M., Menegola, E., Eberini, I., & Moretto, A. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111303 · Cited by 16
Modulation of Pancreatic Neuroendocrine Neoplastic Cell Fate by Autophagy-Mediated Death
Matrood, S., de Prisco, N., Wissniowski, T. T., Wiese, D., Jabari, S., Griesmann, H., Wanzel, M., Stiewe, T., Neureiter, D., Klieser, E., et al. (2020) · Neuroendocrinology · doi:10.1159/000512567 · Cited by 17
“Pan-histone deacetylase inhibitors promote histone acetylation and other nuclear and cytosolic nonhistone proteins, thus facilitating the transcription of autophagy-related genes leading to cell cycle arrest and death [3], as shown in hepatocellular carcinoma and osteosarcoma cells [4-7].”
Aslam, N., Abusharieh, E., Abuarqoub, D. A., Alhattab, D. M., Jafar, H. D., Alshaer, W., Masad, R. J., & Awidi, A. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.584710 · Cited by 18
“Cell cycle arrest was first identified by lower concentrations of HDAC inhibitors that induced G1 arrest by blocking deacetylase activity in tumors [69].”
BackgroundPalicelli, A., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212314 · Cited by 18
“They have also been proposed in clinical trials for the treatment of solid malignancies (including PC) despite poor clinical responses in some cases [173,176].”
BackgroundEpigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
Grumetti, L., Lombardi, R., Iannelli, F., Pucci, B., Avallone, A., Gennaro, E. D., & Budillon, A. (2022) · Cancers · doi:10.3390/cancers14030695 · Cited by 19
“In the past two decades, the acetylation of histone molecules has attracted increasing attention; these molecules are involved in the complex regulation of genome properties, including transcription and DNA repair [4,5].”
BackgroundKhetmalis, Y. M., Shree, B., Kumar, B. V. S., Schweipert, M., Debarnot, C., Fathima, A., Murugesan, S., Trinath, J., Sharma, V., Meyer‐Almes, F., et al. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.134952 · Cited by 17
Manta, A., Kazanas, S., Karamaroudis, S., Gogas, H. J., & Ziogas, D. C. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.026913 · Cited by 31
“It is currently under investigation for the treatment of both hematologic and solid malignancies, as monotherapy or in a combination with other anticancer agents [23,29].”
BackgroundInfluentialRelations between approved platinum drugs and non-coding RNAs in mesothelioma
Biersack, B. (2018) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.08.001 · Cited by 17
“vorinostat, belinostat, romidepsin) and multiple myeloma (panobinostat) [197].”
Dawood, M., Elbadawi, M., Böckers, M., Bringmann, G., & Efferth, T. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110454 · Cited by 17
Molecular diagnostics and biomarkers in cholangiocarcinoma
Brown, Z. J., Patwardhan, S., Bean, J., & Pawlik, T. M. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101851 · Cited by 15
Yousefian, M., Hashemi, M., Eskandarpour, V., Hadizadeh, F., Zarghi, A., & Ghodsi, R. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.137749 · Cited by 16
Vega‐García, N., Malatesta, R., Estella, C., Pérez‐Jaume, S., Esperanza‐Cebollada, E., Torrebadell, M., Català, A., Gassiot, S., Berrueco, R., Ruiz‐Llobet, A., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15436 · Cited by 15
Dagrada, G. P., Rupel, K., Zacchigna, S., Tamborini, E., Pilotti, S., Cavalleri, A., Theune, L. E., Laurini, E., Smith, D. K., Brich, S., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00655 · Cited by 15
Wilson, P. C., Ledru, N., & Humphreys, B. D. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000602 · Cited by 15
Mao, P., He, W.-B., Mai, X., Feng, L., Li, N., Liao, Y., Zhu, C.-S., Li, J., Chen, T., Liu, S.-H., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116599 · Cited by 15
A DNS-metiláció szerepe és megváltozása az öregedés és a daganatos betegségek kialakulása során
Szigeti, K. A., Galamb, O., Kalmár, A., Barták, B. K., Nagy, Z. B., Márkus, E., Igaz, P., Tulassay, Z., & Molnar, B. A. (2018) · Orvosi Hetilap · doi:10.1556/650.2018.30927 · Cited by 20
Trichostatin A promotes GLI1 degradation and P21 expression in multiple myeloma cells
Geng, Y., Liu, J., Xie, Y., Jiang, H., Zuo, K., Li, T., & Liu, Z. (2018) · Cancer Management and Research · doi:10.2147/cmar.s167330 · Cited by 15
Combined Applications of Repurposed Drugs and Their Detrimental Effects on Glioblastoma Cells
Sachkova, A., Sperling, S., Mielke, D., Schatlo, B., Rohde, V., & Ninković, M. (2018) · Anticancer Research · doi:10.21873/anticanres.13099 · Cited by 15
Sodium 4-phenylbutyrate treatment protects against renal injury in NZBWF1 mice
Bonnemaison, M. L., Marks-Nelson, E. S., & Boesen, E. I. (2019) · Clinical Science · doi:10.1042/cs20180562 · Cited by 15
Kasumi, E., & Sato, N. (2019) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.18-103 · Cited by 17
Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies
Makena, M. R., Nguyen, T. H., Koneru, B., Hindle, A., Chen, W.-H., Verlekar, D. U., Kang, M. H., & Reynolds, C. P. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001008 · Cited by 15
Fisher, R. M. A., & Torrente, M. P. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1456052 · Cited by 20
“Some HDACis are already used therapeutically in other diseases such as cancer (Eckschlager et al., 2017).”
BackgroundPROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance
Giardina, S. F., Valdambrini, E., Warren, J. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203110857 · Cited by 15
Hsieh, Y., Lee, K., Cheng, K., Lee, K.-F., Yang, Y., Chu, H., Lin, T., Chen, C., Hsieh, M., Huang, C.-Y., et al. (2023) · Antioxidants · doi:10.3390/antiox12030764 · Cited by 14
“Oxidative stress influences histone modification of H3 and H4 in various ways and, thus, affects a number of post-translational chromatin modifications [35,53].”
BackgroundChloroquine-induced DNA damage synergizes with DNA repair inhibitors causing cancer cell death
Iglesias-Corral, D., García-Vallés, P., Arroyo-Garrapucho, N., Bueno‐Martínez, E., Robles, J. M. R., Ovejero-Sánchez, M., González‐Sarmiento, R., & Herrero, A. B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1390518 · Cited by 14
“Moreover, HDACi have also been shown to exert pleiotropic antitumor effects; they induce the expression of proapoptotic genes, cause cellular differentiation and/or cell cycle arrest (29, 34, 35).”
BackgroundAnticancer properties of histone deacetylase inhibitors – what is their potential?
Kiełbowski, K., Szwedkowicz, A., Plewa, P., Bakinowska, E., Becht, R., & Pawlik, A. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2452338 · Cited by 16
“Belinostat also enhances immune functions, destabilizes microtubules, and reduces the formation of new blood vessels, further contributing to its anticancer effects [71,72].”
Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome
Martinez, X. U., Raimondo, C. D., Abdulla, F. R., Zain, J. M., Rosen, S. T., & Querfeld, C. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.06.004 · Cited by 20
Vitkevičienė, A., Skliutė, G., Žučenka, A., Stoškus, M., Gineikienė, E., Borutinskaite, V. V., Griškevičius, L., & Navakauskienė, R. (2019) · Journal of Oncology · doi:10.1155/2019/6179573 · Cited by 14
Zhang, K., Yao, Y., Tu, Z., Liao, C., Wang, Z., Qiu, Y., Chen, D., Hamilton, D. J., Li, Z., & Jiang, S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0290 · Cited by 14
Zhou, H., Jiang, J., Lu, J., Ran, D., & Gan, Z. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.132200 · Cited by 14
Rubio, C., Ortiz, J. A., Ruiz-Palomares, R., Karaivanova, V., Alberquilla, O., Sánchez‐Domínguez, R., Casalvilla‐Dueñas, J. C., Montalbán-Hernández, K. M., Lodewijk, I., Rodríguez-Izquierdo, M., et al. (2022) · Cancers · doi:10.3390/cancers14020287 · Cited by 14
“Due to their growth-inhibiting and apoptosis-inducing activity, phenyl and sodium butyrate, alone or in combination with other anti-cancer drugs, have been evaluated for the treatment of several malignant tumors [38,39].”
BackgroundNovel antimony( iii ) hydroxamic acid complexes as potential anti-leishmanial agents
Keogan, D. M., Oliveira, S., Sangenito, L. S., Branquinha, M. H., Jagoo, R. D., Twamley, B., dos Santos, A. L. S., & Griffith, D. M. (2018) · Dalton Transactions · doi:10.1039/c8dt00546j · Cited by 17
Minegaki, T., Suzuki, A., Mori, M., Tsuji, S., Yamamoto, S., Watanabe, A., Tsuzuki, T., Tsunoda, T., Yamamoto, A., Tsujimoto, M., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9388 · Cited by 17
“HDACs catalyze the removal of acetyl groups from lysine residues on histones, leading to a condensed chromatin structure, and suppressing the interaction between DNA and transcriptional activators or repressors (5).”
Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma
Vermeulen, K., Ahamed, M., Luyten, K., & Bormans, G. M. (2019) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2019.05.004 · Cited by 15
A Comparative Study of Target Engagement Assays for HDAC1 Inhibitor Profiling
Asawa, R. R., Zakharov, A. V., Niehoff, T., Ata, C., Jadhav, A., Henderson, M. J., Simeonov, A. M., & Martinez, N. J. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219883625 · Cited by 14
Gabano, E., Rangone, B., Perin, E., Caron, G., Ermondi, G., Vallaro, M., Gandin, V., Marzano, C., Barbanente, A., Margiotta, N., et al. (2021) · Dalton Transactions · doi:10.1039/d0dt04135a · Cited by 15
Ekronarongchai, S., Palaga, T., Saonanon, P., Pruksakorn, V., Hirankarn, N., van Hagen, P. M., Dik, W. A., & Virakul, S. (2021) · Thyroid · doi:10.1089/thy.2020.0948 · Cited by 18
“Pan-HDACis, such as SAHA and panobinostat, have been used as anticancer drugs with approval by the US-FDA for T cell lymphoma and multiple myeloma, respectively (24).”
Tseng, Y., Yang, T.-J., Hsu, Y., Liu, J., Tseng, Y., Hsu, T.-W., Lu, Y., Pan, S., Cheng, T.-J. R., & Fang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116042 · Cited by 13
Jiang, Q., Tang, Y.-J., Hu, Q.-L., Wang, B., Ruan, X.-Q., & Zhou, Q. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116315 · Cited by 13
Sirtuin 1 regulates the phenotype and functions of dendritic cells through Ido1 pathway in obesity
de Lima, J., Leite, J. A., Basso, P. J., Ghirotto, B., da Silva, E. M., Menezes-Silva, L., Hiyane, M. I., Goes, C. P., Coutinho, L. L., Andrade‐Oliveira, V., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07125-3 · Cited by 14
Andrade, F. D. O., Furtado, K. S., Heidor, R., Sandri, S., Hebeda, C. B., Miranda, M. L. P., Fernandes, L. H. G., Yamamoto, R. C., Horst, M. A., Farsky, S. H. P., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy190 · Cited by 13
Attia, S. M., Al-Khalifa, M. K., Al‐Hamamah, M. A., Alotaibi, M. R., Attia, M. S. M., Ahmad, S. F., Ansari, M. A., Nadeem, A., & Bakheet, S. A. (2020) · Toxicology · doi:10.1016/j.tox.2020.152507 · Cited by 13
Histone modifiers at the crossroads of oncolytic and oncogenic viruses
Murphy, S. A., Mapes, N. J., Dua, D., & Kaur, B. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.006 · Cited by 14
Yang, J., Yang, S., Liao, Y., Deng, Y., & Jiao, Y. (2023) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2023.108529 · Cited by 13
Muaibati, M., Abasi, A., Zhang, T., Dai, Y., Li, R., Huang, F., Li, K., Tong, Q., Huang, X., & Zhuang, L. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.3 · Cited by 14
Kumar, R. M. R., & Schor, N. F. (2018) · Oncotarget · doi:10.18632/oncotarget.25084 · Cited by 13
Zhu, Y., Yuan, T., Zhang, Y., Shi, J., Bai, L., Duan, X., Tong, R., & Zhong, L. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s211665 · Cited by 13
“The antitumor molecular mechanisms of HDAC inhibitors are not uniform; they may differ in different tumor types and depend on specific agents.(23,24) The results of Western blot analysis showed that AR-42 exerts its anti-ESCC effects mainly through elevating the expression of cell cycle inhibitor p21 and inhibiting th…”
BackgroundRithanya, P., & Ezhilarasan, D. (2020) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-020-00370-7 · Cited by 13
Xu, L., Jiao, J., Sun, X., Sang, W., Gao, X., Pu, Y., Yan, D., Song, X., Sun, C., Liu, M., et al. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.41793 · Cited by 13
“The combined application of drugs is also an effective strategy for the treatment of cancers [17].”
BackgroundAster, R. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00040-0 · Cited by 14
Metadata
- Authors
- Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J.
- Affiliations
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, Prague 5 CZ-150 06, Czech Republic
- Charles University (CZ)
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030/8, Prague 2 CZ-128 43, Czech Republic
- ORCID
- Stiborova, Marie
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1414
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5535906
- OpenAlex
- W2724336500
- Cited by
- 1,206
- References
- 184
- Citations by year
- 2026: 64 · 2025: 107 · 2024: 107 · 2023: 140 · 2022: 164 · 2021: 195 · 2020: 170 · 2019: 164 · 2018: 85 · 2017: 9
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerstvo Zdravotnictví Ceské Republiky (00064203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, epigenetic regulation, histone acetylation, histone acetyltransferase, differentiation therapy, angiogenesis, immune response, vorinostat, romidepsin, belinostat, panobinostat, T-cell lymphoma, multiple myeloma, epigenetic therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Angiogenesis Inhibitors, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Immunomodulation, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
